Vanda Pharmaceuticals (STU:VM4) Dividends per Share : €0.00 (TTM As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Dividends per Share?

Vanda Pharmaceuticals's dividends per share for the three months ended in Dec. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, Vanda Pharmaceuticals's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Vanda Pharmaceuticals Dividends per Share Historical Data

The historical data trend for Vanda Pharmaceuticals's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Dividends per Share Chart

Vanda Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividends per Share

Get a 7-Day Free Trial

Vanda Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Vanda Pharmaceuticals's Dividends per Share

For the Biotechnology subindustry, Vanda Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vanda Pharmaceuticals's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Vanda Pharmaceuticals Dividends per Share Calculation

Dividends paid to per common share.

Vanda Pharmaceuticals (STU:VM4) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Vanda Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-0.076
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Vanda Pharmaceuticals Dividends per Share Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (STU:VM4) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

VNDA:USA 0LKB:UK VM4:Germany

Address

2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037

Website

https://www.vandapharma.com

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Vanda Pharmaceuticals Headlines

No Headlines